CA2306629A1 - Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes - Google Patents

Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes Download PDF

Info

Publication number
CA2306629A1
CA2306629A1 CA002306629A CA2306629A CA2306629A1 CA 2306629 A1 CA2306629 A1 CA 2306629A1 CA 002306629 A CA002306629 A CA 002306629A CA 2306629 A CA2306629 A CA 2306629A CA 2306629 A1 CA2306629 A1 CA 2306629A1
Authority
CA
Canada
Prior art keywords
platelet rich
rich plasma
fibrinogen
plasma
precipitating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306629A
Other languages
English (en)
Inventor
Lou Blasetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvest Technologies Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306629A1 publication Critical patent/CA2306629A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0042—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D17/00—Separation of liquids, not provided for elsewhere, e.g. by thermal diffusion
    • B01D17/02—Separation of non-miscible liquids
    • B01D17/0217—Separation of non-miscible liquids by centrifugal force
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D17/00—Separation of liquids, not provided for elsewhere, e.g. by thermal diffusion
    • B01D17/02—Separation of non-miscible liquids
    • B01D17/04—Breaking emulsions
    • B01D17/047—Breaking emulsions with separation aids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B01D21/01—Separation of suspended solid particles from liquids by sedimentation using flocculating agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B01D21/26—Separation of sediment aided by centrifugal force or centripetal force
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B01D21/26—Separation of sediment aided by centrifugal force or centripetal force
    • B01D21/262—Separation of sediment aided by centrifugal force or centripetal force by using a centrifuge
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B01D21/30—Control equipment
    • B01D21/34—Controlling the feed distribution; Controlling the liquid level ; Control of process parameters
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2221/00—Applications of separation devices
    • B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Thermal Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Ecology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

On obtient des rendements accrus d'un fibrinogène en ajoutant un agent précipitant à du plasma présentant une forte concentration de plaquettes, tel que le plasma enrichi aux plaquettes. Ledit agent précipitant peut être l'un quelconque de nombreux agents connus, y compris le polyéthylèneglycol et le sulfate d'ammonium. Dans la forme de réalisation préférée, on obtient du plasma enrichi aux plaquettes en soumettant le plasma à une centrifugation "douce" d'environ 580G. Une centrifugeuse automatique à décantage multiple et vitesse variable est utilisée, de préférence, pour séparer du sang total anticoagulé en plasma enrichi aux plaquettes et en globules rouges. Les protéines, de préférence des fibrinogènes FXIII et FVIII du plasma enrichi aux plaquettes, sont précipités et les protéines et les plaquettes sont ensuite concentrées par une nouvelle centrifugation.
CA002306629A 1997-10-17 1998-10-16 Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes Abandoned CA2306629A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6226497P 1997-10-17 1997-10-17
US60/062,264 1997-10-17
PCT/US1998/021626 WO1999020288A1 (fr) 1997-10-17 1998-10-16 Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes

Publications (1)

Publication Number Publication Date
CA2306629A1 true CA2306629A1 (fr) 1999-04-29

Family

ID=22041325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306629A Abandoned CA2306629A1 (fr) 1997-10-17 1998-10-16 Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes

Country Status (5)

Country Link
EP (1) EP1023078A4 (fr)
JP (1) JP2001520198A (fr)
CN (1) CN1113656C (fr)
CA (1) CA2306629A1 (fr)
WO (1) WO1999020288A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045760A1 (fr) * 1999-12-22 2001-06-28 Henogen S.A. Produit conçu pour generer des os
CN1303413C (zh) * 2003-06-17 2007-03-07 余伟明 蛋白质、病毒快速富集方法
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CN1908005B (zh) * 2006-08-11 2010-05-12 哈尔滨医科大学 一种复合蛋白沉淀剂
EP2077118A1 (fr) * 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Concentré coagulo-actif de facteurs de croissance de plaquettes et son procédé de préparation
CN105708858A (zh) * 2014-12-05 2016-06-29 国玺干细胞应用技术股份有限公司 富含生长因子的血小板纤维蛋白及其释放液的制备方法
CN104711221B (zh) * 2015-02-15 2017-09-15 第五空间健康管理江苏有限公司 从成人外周血中自动化分离免疫细胞并提取prp的方法
CN107198893A (zh) * 2017-07-01 2017-09-26 张方亮 去白细胞prp的制备方法
CN108478864B (zh) * 2017-08-07 2020-10-23 上海交通大学医学院附属第九人民医院 复合纤维支架
EP4206324A1 (fr) * 2022-01-04 2023-07-05 Phynexus, Inc. Purification de macromolécules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226877A (en) * 1989-06-23 1993-07-13 Epstein Gordon H Method and apparatus for preparing fibrinogen adhesive from whole blood
US5030215A (en) * 1990-01-03 1991-07-09 Cryolife, Inc. Preparation of fibrinogen/factor XIII precipitate
US5585007A (en) * 1994-12-07 1996-12-17 Plasmaseal Corporation Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US5707331A (en) * 1995-05-05 1998-01-13 John R. Wells Automatic multiple-decanting centrifuge

Also Published As

Publication number Publication date
WO1999020288A1 (fr) 1999-04-29
JP2001520198A (ja) 2001-10-30
CN1113656C (zh) 2003-07-09
CN1276725A (zh) 2000-12-13
EP1023078A1 (fr) 2000-08-02
EP1023078A4 (fr) 2004-09-29

Similar Documents

Publication Publication Date Title
EP0813427B1 (fr) Colle plaquettaire, agent d'obturation de plaies
US6444228B1 (en) Autologous fibrin sealant and method for making the same
US7811607B2 (en) Autologous fibrin sealant and method for making the same
US6649072B2 (en) Method for producing autologous platelet-rich plasma
EP2520316B1 (fr) Thrombine isolée du sang et fractions de sang
CA2306629A1 (fr) Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes
US20060261014A1 (en) Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
US20240216433A1 (en) Methods and systems for preparation of mononuclear-platelet rich fibrin matrix, and compounds thereof
US20100086529A1 (en) Methods of making concentrated fibrinogen- and platelet-containing compositions
RU2704256C1 (ru) Способ приготовления аутологичного двухкомпонентного фибринового клея
PL249414B1 (pl) Sposób wytwarzania fibryny bogatopłytkowej

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead